Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Riou, Catherine ^a   Perez Peixoto, Blas ^b   Roberts, Lindi ^a   Ronacher, Katharina ^c   Walzl, Gerhard ^c   Manca, Claudia ^b   Rustomjee, Roxana ^d   Mthiyane, Thuli ^d   Fallows, Dorothy ^b   Gray, Clive M ^a   Kaplan, Gilla ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EOTAXIN; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; ISONIAZID PLUS RIFAMPICIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; CXCL10 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BACTERIAL CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; MIXED INFECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPUTUM CULTURE; TREATMENT DURATION; BLOOD; IMMUNOLOGY; LONGITUDINAL STUDY; MICROBIOLOGY; MIDDLE AGED; SPUTUM;

MYCOBACTERIUM TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CHEMOKINE CXCL10; CYTOKINES; DOWN-REGULATION; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SPUTUM; TUBERCULOSIS, PULMONARY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84861007077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036886     Document Type: Article

References (54)

1. WHO (March 2010) Tuberculosis, Fact sheet No.
2. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, et al. (2006) Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144: 650-659.
3. Wallis RS, Wang C, Doherty M, Onyebujoh P, Vahedi M, et al. (2010) Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Diseases 10: 70-71.
4. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002) Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
5. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, et al. (2009) Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180: 558-563.
6. Sharma SK, Mohan A, Kadhiravan T, (2005) HIV-TB co-infection: epidemiology, diagnosis and management. Indian J Med Res 121: 550-567.
7. Sharma SK, Mohan A, (2004) Extra-pulmonary tuberculosis. Indian J Med Res 120: 317-353.
8. Ribeiro-Rodrigues R, Resende Co T, Johnson JL, Ribeiro F, Palaci M, et al. (2002) Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 9: 818-823.
9. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, et al. (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6: 686-692.
10. Demir T, Yalcinoz C, Keskinel I, Demiroz F, Yildirim N, (2002) sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 6: 155-159.
11. Bajaj G, Rattan A, Ahmad P, (1989) Prognostic value of 'C' reactive protein in tuberculosis. Indian Pediatr 26: 1010-1013.
12. Huang WC, Tseng CW, Chang KM, Hsu JY, Chen JH, et al. (2011) Usefulness of Tumor Marker CA-125 Serum Levels for the Follow-Up of Therapeutic Responses in Tuberculosis Patients with and without Serositis. Jpn J Infect Dis 64: 367-372.
13. Aliyu MH, Salihu HM, Ratard R, (2003) HIV infection and sputum-culture conversion in patients diagnosed with Mycobacterium tuberculosis: a population-based study. Wien Klin Wochenschr 115: 340-346.
14. Rose RM, (1991) Immunology of the lung in HIV infection: the pathophysiologic basis for the development of tuberculosis in the AIDS setting. Bull Int Union Tuberc Lung Dis 66: 15-20.
15. Subramanyam S, Hanna LE, Venkatesan P, Sankaran K, Narayanan PR, et al. (2004) HIV alters plasma and M. tuberculosis-induced cytokine production in patients with tuberculosis. J Interferon Cytokine Res 24: 101-106.
16. Gordeuk VR, Moyo VM, Nouraie M, Gangaidzo IT, Murphree NL, et al. (2009) Circulating cytokines in pulmonary tuberculosis according to HIV status and dietary iron content. Int J Tuberc Lung Dis 13: 1267-1273.
17. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620-4627.
18. Bezuidenhout J, Roberts T, Muller L, van Helden P, Walzl G, (2009) Pleural tuberculosis in patients with early HIV infection is associated with increased TNF-alpha expression and necrosis in granulomas. PLoS One 4: e4228.
19. Bekker LG, Moreira AL, Bergtold A, Freeman S, Ryffel B, et al. (2000) Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun 68: 6954-6961.
20. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
21. Bekker LG, Maartens G, Steyn L, Kaplan G, (1998) Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 178: 580-584.
22. Mendez S, Traslavina R, Hinchman M, Huang L, Green P, et al. (2009) The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother 53: 5114-5121.
23. Dalhoff A, Shalit I, (1996) Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359-371.
24. Morikawa K, Watabe H, Araake M, Morikawa S, (1996) Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 40: 1366-1370.
25. Kapplan G, Luster AD, Handcock G, Cohn ZA, (1987) The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J exp Med 166: 1098-1108.
26. Liu M, Guo S, Hibbert JM, Jain V, Singh N, et al. (2011) CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22: 121-130.
27. John SH, Kenneth J, Gandhe AS, (2011) Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies. Biomarkers.
28. Whittaker E, Gordon A, Kampmann B, (2008) Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 3: e3901.
29. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, et al. (2010) IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 10: 333-341.
30. Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, et al. (2010) Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One 5: e12577.
31. SA TUBERCULOSIS STRATEGIC PLAN FOR SOUTH AFRICA, (2007-2011) Department of Health Republic of South Africa.
32. Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, et al. (2011) Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One 6: e19617.
33. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, et al. (2003) The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 307: 122-134.
34. Keating SM, Golub ET, Nowicki M, Young M, Anastos K, et al. (2011) The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women. Aids.
35. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, et al. (2005) IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 7: 1-8.
36. Supriya P, Chandrasekaran P, Das SD, (2008) Diagnostic utility of interferon-gamma-induced protein of 10 kDa (IP-10) in tuberculous pleurisy. Diagn Microbiol Infect Dis 62: 186-192.
37. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P, (2009) IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2: 19.
38. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G, (2009) Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 156: 69-77.
39. Kabeer BSA, Raja A, Raman B, Thangaraj S, Leportier M, et al. (2011) IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 11: 135-144.
40. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
41. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L, (2011) Signal transduction by vascular endothelial growth factor receptors. Biochem J 437: 169-183.
42. Tammela T, Petrova TV, Alitalo K, (2005) Molecular lymphangiogenesis: new players. Trends Cell Biol 15: 434-441.
43. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, et al. (2003) Transgenic delivery of VEGF to the mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102: 161-168.
44. Park HY, Hahm CR, Jeon K, Koh WJ, Suh GY, et al. (2012) Serum vascular endothelial growth factor and angiopoietin-2 are associated with the severity of systemic inflammation rather than the presence of hemoptysis in patients with inflammatory lung disease. Yonsei Med J 52: 369-376.
45. Sakaguchi I, Ikeda N, Nakayama M, Kato Y, Yano I, et al. (2000) Trehalose 6,6'-dimycolate (Cord factor) enhances neovascularization through vascular endothelial growth factor production by neutrophils and macrophages. Infect Immun 68: 2043-2052.
46. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, et al. (2004) Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 125: 2156-2159.
47. Abe Y, Nakamura M, Oshika Y, Hatanaka H, Tokunaga T, et al. (2001) Serum levels of vascular endothelial growth factor and cavity formation in active pulmonary tuberculosis. Respiration 68: 496-500.
48. Matsuyama W, Hashiguchi T, Matsumuro K, Iwami F, Hirotsu Y, et al. (2000) Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. Am J Respir Crit Care Med 162: 1120-1122.
49. Costa C, Incio J, Soares R, (2007) Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10: 149-166.
50. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, et al. (2007) Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 85: 613-621.
51. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM, (2008) Biomarkers for TB treatment response: challenges and future strategies. J Infect 57: 103-109.
52. Wallis R, Johnson JL, (2005) The Role of Surrogate Markers in the Clinical Evaluation of Anti-tuberculous Chemotherapy. Curr Med Chem- Anti-Infective Agents 4: 1-8.
53. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, et al. (2010) Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375: 1920-1937.
54. Columb MO, Sagadai S, (2006) Multiple comparisons. Current Anaesthesia & Critical Care 17: 233-236.